Evidence map›Paper›PMID 42728728›Full record

ArticleMethods of information in medicine2026

Privacy-Preserving Linkage of Distributed Biological, Clinical, and Imaging Data Supporting Artificial Intelligence in Pediatric Oncology.

Dieter Hayn, Martin Baumgartner, Karl Kreiner, Emanuel Sandner, Bernhard Jammerbund, Martin Schalling, Ulrike Poetschger, Vanessa Duester, Blanca Martinez de Las Heras, Adela Cañete Nieto and 4 more

Abstract read
In one paragraph

Article in Methods of information in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dieter HaynAIT Austrian Institute of Technology GmbH, Center for Health & Bioresources, Digital Health Information Systems, Styria, Austria, Graz.
Martin BaumgartnerAIT Austrian Institute of Technology GmbH, Center for Health & Bioresources, Digital Health Information Systems, Styria, Austria, Graz.
Karl KreinerAIT Austrian Institute of Technology GmbH, Center for Health & Bioresources, Digital Health Information Systems, Styria, Austria, Graz.
Emanuel SandnerAIT Austrian Institute of Technology GmbH, Center for Health & Bioresources, Digital Health Information Systems, Styria, Austria, Graz.
Bernhard JammerbundAIT Austrian Institute of Technology GmbH, Center for Health & Bioresources, Digital Health Information Systems, Styria, Austria, Graz.
Martin SchallingSt. Anna Children's Cancer Research Institute (CCRI), Austria, Vienna.
Ulrike PoetschgerSt. Anna Children's Cancer Research Institute (CCRI), Austria, Vienna.
Vanessa DuesterSt. Anna Children's Cancer Research Institute (CCRI), Austria, Vienna.
Blanca Martinez de Las HerasLa Fe University and Polytechnic Hospital, Paediatric Haemato-oncology Unit, La Fe Health Research Institute (IIS La Fe), Spain, Valencia.
Adela Cañete NietoLa Fe University and Polytechnic Hospital, Paediatric Haemato-oncology Unit, La Fe Health Research Institute (IIS La Fe), Spain, Valencia.
Ana Jiménez-PastorQuantitative Imaging Biomarkers in Medicine, QUIBIM, Spain, Valencia.
Luis Martí-BonmatíLa Fe University and Polytechnic Hospital & Biomedical Imaging Research Group, Department of Medical Imaging, Spain, Valencia.
Ruth LadensteinSt. Anna Children's Cancer Research Institute (CCRI), Austria, Vienna.
Günter SchreierAIT Austrian Institute of Technology GmbH, Center for Health & Bioresources, Digital Health Information Systems, Styria, Austria, Graz.

Funding

European Commission 825575, 826494
6 · The paper itself

Abstract

Background: Cancer remains the leading cause of disease-related mortality in children over the age of one in Europe, with over 35,000 new pediatric cases and more than 6,000 deaths annually. Due to the rarity of pediatric cancers, clinical trial protocols often substitute for formal treatment guidelines, resulting in many children being enrolled in multiple trials, with biological samples and genomic data stored in various biobanks. Data collection in pediatric oncology is challenging, with sparse data acquired over extended periods, underscoring the need for optimal utilization of all available information through linked, privacy-preserving datasets. Methods: Here, we report the development of a distributed, privacy-preserving data infrastructure for the PRIMAGE project, a European initiative aimed at supporting artificial intelligence (AI)-driven image analysis for pediatric cancer prognostics. The infrastructure leverages the European Patient Identity (EUPID) Services for Privacy-Preserving Record Linkage, enabling pseudonymized data integration across clinical, biological, and imaging sources. The system incorporates EUPID's hashing and phonetic matching protocols to pseudonymize patient identifiers and link distributed datasets, facilitating secondary data use in compliance with the General Data Protection Regulation. Results: Data from over 700 neuroblastoma patients from European trials and hospitals were linked and uploaded to the PRIMAGE platform, where AI models predict clinical outcomes. Conclusion: This infrastructure successfully facilitated AI model development, advancing pediatric oncology research, and offering a scalable framework for future European health data initiatives, such as the European Health Data Space.

Indexed as

Artificial IntelligenceConfidentialityMedical OncologyPediatricsPrivacyChildEuropeHumansNeuroblastoma

Identifiers

PMID42728728
PMCPMC13668395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.